Literature DB >> 16487453

Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole.

Michele Raja1.   

Abstract

Aripiprazole, an antipsychotic recently introduced for clinical use, may worsen psychotic symptoms, even at low dose. In other cases, aripiprazole may exercise an antipsychotic action and induce extrapyramidal side-effects, even at low dose. There are no clear-cut criteria to differentiate the patients whose psychotic symptoms will or will not respond to aripiprazole favourably. Conversely, the effectiveness on negative symptoms seem consistent both in patients with or without antipsychotic response. A low dose may be indicated at the beginning of treatment to assess the kind of response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487453     DOI: 10.1017/S1461145706006523

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  5 in total

1.  Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide.

Authors:  François Montastruc; Rui Nie; Simone Loo; Soham Rej; Sophie Dell'Aniello; Joëlle Micallef; Samy Suissa; Christel Renoux
Journal:  JAMA Psychiatry       Date:  2019-04-01       Impact factor: 21.596

2.  Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.

Authors:  Chi-Un Pae; Alberto Chiesa; Laura Mandelli; Ashwin A Patkar; Sara Gibiino; Alessandro Serretti
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

Authors:  Shih-Fen Chen; Yu-Chih Shen; Chia-Hsiang Chen
Journal:  Psychopharmacology (Berl)       Date:  2009-04-23       Impact factor: 4.530

Review 4.  A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.

Authors:  Hiroyoshi Takeuchi; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-06-05       Impact factor: 4.530

5.  Management of antipsychotic-induced hyperprolactinemia.

Authors:  Ashley Tewksbury; Amy Olander
Journal:  Ment Health Clin       Date:  2016-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.